Nanoscope Therapeutics CEO Sulagna Bhattacharya Joins BIO Health Section Governing Board

Nanoscope Therapeutics CEO Sulagna Bhattacharya Joins BIO Health Section Governing Board

DALLAS, TX (February 13, 2023) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Sulagna Bhattacharya, Chief Executive Officer and Co-Founder of Nanoscope Therapeutics, has been named to the Health Section Governing Board of the Biotechnology Innovation Organization (BIO) Board of Directors.

Ms. Bhattacharya was named to the BIO Board of Directors in February 2022 and currently serves on the Emerging Companies Section Governing Board, on which she will continue to serve in addition to her new role on the Health Section Governing Board. She has also been selected as a member of BIO’s Nominating Committee.

The BIO Health Section Governing Board is comprised of thought leaders who bring their expertise to major issues affecting their specific area of the biotechnology industry.

“Accelerating development of innovative therapies is a true passion of mine,” said Ms. Bhattacharya. “I look forward to working with the other biopharma leaders on the BIO Health Section Governing Board to promote policy strategies that enable this acceleration across the Biotech sector.”

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top-line data expected Q1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

 

On February 13, 2023   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.